Hey rjs, well, then we actually are of opposite

New Post Public Reply Private Reply Replies (1) Message Board
Zolis_onkel rjs9787 #26754
402
Hey rjs,

well, then we actually are of opposite opinions.

You wrote that "And no one heard anything taking several more weeks..." and that this is only my own interpretation.

Hmmm, if I read the post from skipper, where he quotes a message from
Joe, that

Quote:
"The results were received. Now they need to be certified by COVANCE, Elispot, Univ. of San Diego, CTL, then a statistical analysis has to be performed.

Further reviews are then needed by:
Advisory board;
Head of FDA pediatrics;
NIH;
DOD (me I’m not sure about this one)"

With all that listed it is not far fetched to assume that this will at least take "a couple of more weeks", right?

Some additional points that I'd like to add:
1) Whatever Mr Purcell lectured about might have been interesting for you, as you were able to follow, but it was rather dull for me, as I only understand a fraction of it, both due to the terrible sound quality and the fact that I don't happen to be a biochemist, but a physicist. So to be honest, I personally wouldn't have needed that biochemistry lecture. It would have been sufficient for me to hear, that the tests were very successful and they are now being handed into the FDA as basis for the IND application to gain approval to start the clinical trials.
While I didn't need the first, and wanted the second, I received the first and was put off about the second. That is what I mean when I write that I see a disconnect in the communication between GNBT's management team and us, their shareholders.
I want to hear the success stories and reliable timelines on how things will continue to progress, and they - excuse me - bore me with biochemistry details.
2) Honestly, I have no problem with waiting another 6 weeks or so. I have learned to be patient, not just because I have already been a long time GNBT shareholder for a very long time, LOL. But I am asking, or even demanding an open an reliable communication between GNBT's management and myself, such that I can count on information and timelines given to me. If I would have been told during the CC, that in 10 days GNBT will receive lab test results, and then the chain of next steps need to be happening, and step 1 takes 3 days, step 2 takes 1 week, ... and it all will take 6 weeks total to accomplish and only then the IND application to the FDA can happen, and another 4 weeks later the clinical trials can start. I guess that would have been sufficient for me. Especially, if I woulld receive a first update 3 days later, telling me that step1 is complete. BECAUSE, in such a case, I can ask myself, is it worth it for me to stay invested for another 6 weeks, and am I willing to wait for such a long time. And I guess, if it would be reliably communicated to me, I would be willing to be patient and stay invested. But what I personally find catastrophic is the assumption Joe seems to constantly make is that I know what he means 6 weeks, when he says "in the coming days", or that we all know that once the results have been received that it requires all the additional steps, and I cannot expect to receive a PR immediately afterwards that gives me the executive summary, of "Thumbs up, test results are very positive, and now it will take about 6 more weeks, before we can start with the clinical trials". The way it is carried out by the GNBT management is what I would call "Salami tactic", ie. you deliver the full information slice after slice. That is terrible, to be honest.

3) I know that I repeat myself, but what I still don't really get is that I continue to have the impression that they seem to be absolutely in no rush. I understand, as docj has put it, that this is not baking bagels for Sunday's breakfast, but to stay in that metaphor no bakery is able to sell bagels for the Sunday breakfast on a Monday afternoon. If you catch my drift, what I mean to say by this is that of course everything needs to be carried out very thoroughly, but why am I left with the impression that with GNBT EVERYTHING always takes significantly longer than for the competition. Are they really aware that they are still in a race for the best vaccine? Is this just my fals impression here? I don't think so, and we might have the best ever vaccine, but when everybody has received a first vaccination and/or the virus has already significantly mutated, it will surely be too late even FOR THE BEST EVER "Complete Vaccine".

I know, I know, it is up to me to decide whether it is worth for me to stay invested or move on, but for such a decision I would need reliable timelines to think for myself whether this will still lead to a FDA approved CV-19 vaccine when there still would be a market for it, or not. Because, in the end, the best ever vaccine is only as good as it is useful and fast enough available for a mass market.

So let's really hope that you are right with your assumption that we will receive an update via PR early next week, otherwise I am sure that a lot of people are getting very impatient very soon. I am not talking about myself here in particular, but I have endless discussions on my German message board with a bunch of users, who already now talk about this being fraud. I am surely not one of them, but for sure I am frustrated.
As, I guess, most of us agree, this is "show me time" for GNBT, and yet another delay of showing us the facts is surely not going to help the PPS to increase, as we are all hoping for, right?

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Supply Maverick Simplifies Global Shipping Processes

Updated Category News Views 5

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Continue Reading
Fermi's Founder Pushes for Board Overhaul: What's Next?

Updated Category News Views 4

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 12

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
High-Grade Copper Spurs Optimism for PolarX in Alaska

Updated Category News Views 4

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Continue Reading
Americas Cardroom's Poker Series Hits $7.2M Haul

Updated Category News Views 6

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Continue Reading
QuickFi Nabs Top Finovate Award for Fourth Time

Updated Category News Views 5

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 5

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 14

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 4

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 6

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

Atos Annual General Meeting Highlights and Board Changes

Updated Category News Views 133

Key Highlights from Atos Annual General Meeting Atos, a global digital transformation leader, has officially convened its Annual General Meeting (AGM) focused on enhancing corporate governance and approving pivotal financial statements. This meeting aims to highlight vital changes within the Board of Directors while ensuring stakeholders are informed and engaged. Overview...

Continue Reading
NRSInsights Reports Robust Growth in Retail Sales for October

Updated Category News Views 59

October Retail Sales Growth Highlights October same-store sales saw a noteworthy increase of 3.7% year-over-year, indicating a strong consumer demand. In a recent report from NRSInsights, a prominent analytics provider leveraging data from the National Retail Solutions (NRS) point-of-sale system, retail sales for October 2024 have shown promising trends. Approximately...

Continue Reading
Understanding Alliance Witan PLC's Net Asset Valuation Insights

Updated Category News Views 112

Understanding Alliance Witan PLC's Financial Standing Alliance Witan PLC stands out in the investment landscape, offering its shareholders a detailed look at their Net Asset Value (NAV). As of the latest reporting date, the financial metrics reveal significant information pertaining to the company's performance and shareholder value. Net Asset Value Calculation At the...

Continue Reading
Discover the Remarkable Returns of Vulcan Materials Stock

Updated Category News Views 141

Unveiling Vulcan Materials Company Stock Performance Vulcan Materials Co. (NYSE: VMC) has been a noteworthy performer in the stock market over the past 15 years, surpassing market expectations with a commendable annual return of 15.1%. This stock has consistently outperformed the market, achieving an admirable 2.86% advantage annually. With a current market capitalization...

Continue Reading
Vroom Unveils Comprehensive Long-term Vision for Growth

Updated Category News Views 63

Vroom Reveals New Strategic Plan for Future Success Vroom, Inc. (Nasdaq: VRM) has unveiled its long-term strategic plan, offering a clear roadmap that outlines the company's aspirations and critical initiatives for the future. This announcement was made through an investor presentation, which elaborated on how Vroom plans to improve its operational efficiency and overall...

Continue Reading